Modern Diagnostic IPO Analyzed

Modern Diagnostic & Research Centre recently finished its Initial Public Offering (IPO) and started trading on the stock market. The company raised a significant amount of money – ₹36.89 crore – by selling shares to investors. This successful debut is worth examining closely to understand its implications.

Key Points

• Shares started trading at a 10.56% premium over the IPO price.
• Grey market predictions were slightly lower than the actual listing price.
• The IPO was heavily oversubscribed by investors, a strong indicator of interest.
• Non-institutional investors led the subscription, showing considerable confidence.
• Funds will be used for equipment, working capital, and debt reduction.
• The IPO demonstrated a robust market appetite for this type of company.

About the IPO

The IPO was entirely about selling new shares to the public. Modern Diagnostic offered 4.1 million shares at a price between ₹85 and ₹90. Investors were really interested, with subscriptions being 350.49 times higher than the number of shares available.

Who Bought the Shares?

Most of the investors who wanted shares were small investors (non-institutional investors) who subscribed 519.38 times to their portion. Qualified Institutional Buyers (QIBs) and Retail Investors also showed strong interest, though to a lesser extent.

How the Money Will Be Used

The company plans to use the money raised to buy new medical equipment for its labs and centers. About ₹8 crore will be used for daily operations and ₹1 crore to pay off some debt. The remaining funds will be used for general business expenses.

Important Numbers

The IPO opened for subscription from December 31, 2025, to January 2, 2026. The allotment of shares was finalized on January 5, 2026, at a price of ₹90 per share, which was the highest price offered in the IPO.

A successful IPO signals investor confidence in the company’s growth potential.